Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis.
Open Access
- 1 January 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 140 (1) , 59-61
- https://doi.org/10.4049/jimmunol.140.1.59
Abstract
In order to assess the importance of interleukin 2 receptor (IL-2R)-positive activated lymphocytes and macrophages in the pathogenesis of autoimmunity, we tested the prophylactic therapeutic efficacy of an anti-IL-2R (M7/20) monoclonal antibody, which recognizes the 55-kDa subunit of the heterodimeric IL-2R in two distinct models: the nonobese diabetic mouse and the NZB x NZW F1 hybrid with lupus. Treatment with anti-IL-2R monoclonal antibody suppressed autoimmune insulitis in nonobese diabetic mice and lupus nephritis in the NZB x NZW F1 hybrid. These studies indicate that highly selective targeting to activated lymphocytes and macrophages expressing the IL-2R provides a discrete method of dampening autoimmunity.This publication has 2 references indexed in Scilit:
- Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.Proceedings of the National Academy of Sciences, 1986
- Dual parameter flow cytometric analysis of DNA content, activation antigen expression, and T cell subset proliferation in the human mixed lymphocyte reaction.The Journal of Immunology, 1984